Abstract: An enclosed multi-dimensional system for converting electromagnetic (EM) energy into electricity. An electromagnetic energy convertor (EMEC) device comprises a plurality of electromagnetic (EM) energy converting cells disposed in a single-piece, at-least-partially transparent, insulating medium selected from a list of luminescent, transmissive, absorptive, diffusive, refractive, dispersive, conductive, and dielectric materials or a combination thereof. The medium facilitates the propagation of the electromagnetic energy within the EMEC device and helps to optimize its conversion to electricity by the plurality of electromagnetic (EM) energy converting cells. The plurality of electromagnetic (EM) energy converting cells are disposed at least partially within the medium.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: Chronic tobacco smoke exposure (TSE)-induced lung injury includes increased alveolar and airway inflammation, type II alveolar epithelial cells (A2Cs) senescence and apoptosis, and mucus hypersecretion by airway epithelial cells (AECs) that can be treated by the caveolin-1 peptide CSP7 (SEQ ID NO:1). Caveolin-1 and p53 mediated induction of plasminogen activator inhibitor-1 (PAI-1) expression by interleukin 17A, TSE, pollution and other causes leads to lung injury, which can be abrogated by CSP7 treatment, which abolishes A2Cs senescence and apoptosis and AEC mucus hypersecretion. CSP7 treatment of lung tissue of patients with TSE-induced lung injury decreases A2C apoptosis and AEC mucus hypersecretion. Lung injury with A2Cs senescence and apoptosis and AEC mucus hypersecretion caused by TSE-induced PAI-1 expression in lung tissue of patients is abolished by CSP7.

Abstract: The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.

Abstract: The current disclosure describes effective therapeutic treatments and diagnostic/prognostic methods for colorectal cancer based on the expression or activity level of biomarkers. Aspects of the disclosure relate to a method for treating a subject for colorectal cancer, the method comprising treating the subject for colorectal cancer after the expression level of one or more biomarker genes from Table 1, Table 2, Table 3, Table 4, Table 5, Table S2, Table S3, Table S4, Table S5, FIG. 4A, and/or FIG. 4B has been determined in a sample from the subject.

Abstract: Methods for converting mixtures of anthocyanins occurring in fruit or vegetable juice or extract into particular anthocyanin molecules having desirable colorant properties are provided herein. The method of the present disclosure can be employed to increase the amount of particular anthocyanin molecules, while lowering the total number of anthocyanin molecules present in the natural juice and/or extract. The disclosure is also directed to anthocyanin molecules prepared by the methods of present disclosure and to enzymes capable of catalyzing reactions that provide such effects.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: In various embodiments method are provided for generating expression cassettes and gene therapy vectors comprising those cassettes that recapitulate the spatiotemporal pattern of expression of the endogenous gene. In certain embodiments the methods comprise (i) selecting a target gene; (ii) identifying putative regulatory elements associated with the target gene; (iii) determining if the regulatory element is a key regulatory element and (iv) providing a list of the key regulatory elements identified in step (iii).

Abstract: Present implementations are directed to nonvolatile memory devices with charge trap transistor structures. Example implementations can include a method of memory storage, by programming a first data node operatively coupled to a first charge trap transistor to a first level above a threshold, decreasing, below the threshold, a first voltage at the first charge trap transistor, increasing, above the threshold, the first voltage at the first charge trap transistor, and reprogramming, the first data node to the first level, in response to an interruption of the first voltage at the first charge trap transistor caused by the decreasing and the increasing.

Abstract: A stent and a system comprising a stent and a stent deployment catheter are disclosed. The stent comprises an elongated tubular body defining a longitudinal axis and including a proximal end, a distal end, and a central lumen extending between the proximal end and the distal end. The central lumen is configured for passage of a guide wire therethrough. The stent further comprises a tapered and/or frustoconical distal tip portion disposed at the distal end of the elongated tubular body, wherein the distal tip portion comprises one or more spiral threads. The stent deployment catheter comprises an inner sheath configured to be slidably disposed within the central lumen of the elongated tubular body; and an outer sheath configured to be slidably disposed over the inner sheath. The stent and stent deployment catheter can be configured for placement of the stent within a pancreaticobiliary duct.

Abstract: Described herein are methods, materials, kits, devices, and assays for use in screening, detection, and treatment of diabetes, including diabetes mellitus and gestational diabetes mellitus (GDM). The amount of a plurality of metabolic markers present in a test sample obtained from the subject is measured, followed by comparing the amount of the metabolic markers present in the test sample to reference levels of the markers; and identifying a subject as susceptible to, or as having, diabetes when the amount of each of the measured markers present in the test sample is increased or decreased relative to the reference levels. Also provided is a method of treating diabetes in a subject when the amount of each of the measured markers present in the test sample is increased or decreased relative to the reference levels.

Abstract: Systems and methods for fabricating an optoelectronic transceiver with a tunable traveling wave modulator and an analog coherent receiver to transmit and receive wavelength-multiplexed optical signals in accordance with embodiments of the invention are disclosed. In one embodiment, a network switch includes a plurality of ports configured to transmit and receive optical signals and electrical current signals, a plurality of optoelectronic transmitters using a traveling wave modulator and driver biasing, and a plurality of analog coherent receivers.

Abstract: Systems and methods are provided for excitation spectral microscopy using frame-synchronized acousto-optic scanning of fluorescent excitation wavelengths. Linear unmixing of the images of targets of components that are individually labeled with different fluorophores can be simultaneously imaged with high temporal resolution and low crosstalk and the local abundance of each fluorophore at each pixel can be quantified. Fluorophore decomposed micrographs of the sample can be obtained by rendering the abundance in each pixel as an image.

Abstract: The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

Abstract: Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

Abstract: A surgical practice system including a box that defines an inner compartment, and multiple articulable arms mounted to the box within the inner compartment, each arm including a gripping element provided at its distal end that is configured to grip an object.

Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Abstract: The invention provides for novel glaucoma surgical devices comprising a microfluidic meshwork. The meshwork comprises interconnected, cellular-dimensioned microfluidic channels. Excess fluid in the eye can be drained and diffused through the microfluidic channels. The meshwork is porous and highly flexible, affording mechanical compliance similar to that of eye tissue. The meshwork minimizes foreign body reactions to the implant, decreasing fibrosis and capsule formation.

Abstract: Slurry compositions, tape casting binder systems and fabrication methods for the fabrication of lithium-garnet electrolyte scaffolds for use in solid state batteries and other devices are provided. Slurry compositions may be optimized mixtures of LLZO powder, a dispersant, a lithium salt, a wetting agent a binder, a plasticizer and at least one solvent. The optimized ceramic slurry compositions may include MgO as a sintering additive to improve density and ionic conductivity of the doped-LLZO sheets and produce a fine-grained microstructure. Sintering protocols for cast slurries of commercially available doped LLZO powders eliminate the requirement of mother-powder coverings or externally applied pressure. An environmentally friendly water-based system using methylcellulose as a binder is also provided producing green tape and final properties comparable to those obtained with organic solvent-based systems.

Abstract: A new male pistachio cultivar (Pistacia vera L.) designated as ‘UC Westside’, to be used advantageously as a pollenizer for commercial female pistachio varieties. ‘UC Westside’ blooms later in the spring than most existing male pistachio cultivars and is particularly characterized by a reduced juvenility period, dense blooms in years with low chill, good pollen viability, and improved bloom synchrony with standard female pistachio varieties, especially ‘Kerman’. It may be used as a replacement for the male cultivar ‘Peters’.